+ All Categories
Home > Documents > In silico studies of the buPAG2

In silico studies of the buPAG2

Date post: 09-Apr-2018
Category:
Upload: bhaskar-ganguly
View: 218 times
Download: 0 times
Share this document with a friend

of 30

Transcript
  • 8/7/2019 In silico studies of the buPAG2

    1/30

    Bhaskar Ganguly*, Ritu Shah, Shiv Prasadand H.P. Gupta

  • 8/7/2019 In silico studies of the buPAG2

    2/30

    PAG

    1st isolated by Butler, 1982 in bovines from outerepithelial cell layer (chorion/ trophectoderm)

    Expressed 7th day onwards

    Ruminants have > 100 PAG genes

    Expressed in pre-placental trophoblast, and post-implantation trophectoderm

    Acts as local immunosuppresant

    Also k/a Preg. Sp. Pr. B (PSPB), Preg. Sp. Pr. (PSP)-60

    buPAG 1 is the major subfamily, PAG 2 is the majormember of the subfamily

    Bubaline Pregnancy AssociatedGlycoprotein (buPAG)

    PAGFamily

    buPAG

    1

    buPAG

    2

    buPAG

    8

  • 8/7/2019 In silico studies of the buPAG2

    3/30

    STEP 5

    SEQUENCE ANALYSIS

    cDNA Amino Acid

    SEQUENCE

    STRUCTURAL & FUNCTIONALANNOTATION

    PHYSICO-CHEMICALCHARACTERISATION

    STRUCTURE DETERMINATION

    STEP 1

    STEP 2

    STEP 3

    STEP 4

  • 8/7/2019 In silico studies of the buPAG2

    4/30

    STEP 1

    TRANSLATE

    Cloning using PAG2 specific primers

    & Sequencing

    GenBank Accession:

    GU433184.1

  • 8/7/2019 In silico studies of the buPAG2

    5/30

    STEP 2

    Number of amino acids: 99

    Amino acid composition:Ala 4.0% Arg 2.0% Asn 4.0% Asp 6.1% Cys 3.0% Gln 3.0%Glu 2.0% Gly 11.1% His 1.0% Ile 10.1% Leu 7.1% Lys 2.0%Met 1.0% Phe 9.1% Pro 7.1% Ser 12.1% Thr 7.1% Trp 1.0%

    Tyr 3.0% Val 4.0%

    Number of negatively charged residues (Asp + Glu): 8Number of positively charged residues (Arg + Lys): 4

    Atomic composition: C483H725N117O145S4Total number of atoms: 1474

  • 8/7/2019 In silico studies of the buPAG2

    6/30

    STEP 3

    3D-JigSaw

    ESyPred

    SwissModel

    TASSER

    Structural Analysis &

    Verification Server

    (SAVES)

    Quality Factorranged about 38 %(ESyPred) to 82 %

    (SwissModel)

    Quality Factorgreater than 85 %

  • 8/7/2019 In silico studies of the buPAG2

    7/30

    buPAG.pdb(TASSER)

  • 8/7/2019 In silico studies of the buPAG2

    8/30

    STEP 4

    Molecular weight: 10619.0 (10.6 kDa) (Poor antigen)

    Theoretical pI: 4.40

    Extinction coefficients: (280 nm; measured in water)997010095 M-1cm-1 (Cys reduced Cystine)Absorbance (0.1% =1 g/l): (280 nm; measured in water)

    0.939 - 0.951 (Cys reduced Cystine)

    Estimated half-life:4.4 hrs (mammalian reticulocytes, in vitro) (Poor antigen)

    Instability index: 64.70 (Unstable) (Poor antigen)Aliphatic index: 82.73

    Grand avg. hydropathicity (GRAVY): 0.230 (Poor antigen)

    ProtParam

  • 8/7/2019 In silico studies of the buPAG2

    9/30Hydrophobicity Plot (Kyte Doolittle)

  • 8/7/2019 In silico studies of the buPAG2

    10/30

    Secondary structure

  • 8/7/2019 In silico studies of the buPAG2

    11/30

    Front view Left view

    Top view

    STEP 5

    TASSER

  • 8/7/2019 In silico studies of the buPAG2

    12/30

    hypothetical Ligand

    probable Active Residues

    Six active residues;four on surface, twowithin

    One prominentligand binding siteon surface of themolecule

    TASSER

  • 8/7/2019 In silico studies of the buPAG2

    13/30

    probable Active Residues

    Four surface active

    residues:

    Ala 27

    Ser 29

    Lys 89

    Ile 92

    One prominent

    ligand binding site

    on surface of the

    molecule

    ligand bound to molecular surface TASSER

  • 8/7/2019 In silico studies of the buPAG2

    14/30

    PdbSum

  • 8/7/2019 In silico studies of the buPAG2

    15/30

    PdbSum

  • 8/7/2019 In silico studies of the buPAG2

    16/30

    3DLigandSite

  • 8/7/2019 In silico studies of the buPAG2

    17/30

    The bubaline Pregnancy Associated

    Glycoprotein (buPAG) is:

    Inducible,

    Extracellular,

    Aspartic Endopeptidase, and

    Involved in intermediary metabolism.

    ConFunc

  • 8/7/2019 In silico studies of the buPAG2

    18/30

  • 8/7/2019 In silico studies of the buPAG2

    19/30

  • 8/7/2019 In silico studies of the buPAG2

    20/30

  • 8/7/2019 In silico studies of the buPAG2

    21/30

  • 8/7/2019 In silico studies of the buPAG2

    22/30

  • 8/7/2019 In silico studies of the buPAG2

    23/30

    Mechanism of action of Aspartic Endopeptidases

  • 8/7/2019 In silico studies of the buPAG2

    24/30

    Mapping the catalytic site

  • 8/7/2019 In silico studies of the buPAG2

    25/30

    Mapping the catalytic site

  • 8/7/2019 In silico studies of the buPAG2

    26/30

    Mapping the catalytic site

  • 8/7/2019 In silico studies of the buPAG2

    27/30

    Mapping the catalytic site

  • 8/7/2019 In silico studies of the buPAG2

    28/30

    Mapping the catalytic site

    Asp 90Asp 96

    C atom ofpolyD

  • 8/7/2019 In silico studies of the buPAG2

    29/30

    SIGNIFICANT FINDINGS

    Physical and bio-chemical properties were predicted

    Characteristics for immunological optimization were

    identified

    3-D model of the protein was obtained

    Structural characteristics of the protein were identified

    The active catalytic site was mapped to its molecular

    detail

    The study shall make possible the optimization of

    inhibitors for homologous molecules to allow a

    physiological dissection of the exact role of buPAG 2

  • 8/7/2019 In silico studies of the buPAG2

    30/30


Recommended